A Hepatic Impairment Study for PF-04965842.

• ClinicalTrials.gov Identifier: NCT03626415
• Recruitment Status: Completed
• First Posted: August 13, 2018
• Results First Posted: May 18, 2020
• Last Update Posted: May 18, 2020
• Sponsor: Pfizer
• Information provided by (Responsible Party): Pfizer

Study Description

Brief Summary:

This is a Phase 1 non randomized, open label, single dose, parallel cohort study to investigate the effect of hepatic impairment on the PK, safety and tolerability of PF 04965842.

Condition or disease	Intervention/treatment	Phase
Hepatic Impairment	Drug: PF-04965842	Phase 1

Detailed Description:

A minimum of 24 subjects with normal, mild or moderate hepatic function will be enrolled into the study, with approximately 8 subjects in each cohort. The Child Pugh classification score will be utilized to assess entry criteria and to assign subjects into the appropriate hepatic impairment group. For individual subjects, the total maximum duration of study participation from the Screening visit to the end of clinical research unit (CRU) stay is approximately 31 days and approximately 63 days from the Screening visit to the Follow up contact.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 24 participants
• Intervention Model: Parallel Assignment
• Intervention Model Description: Recruitment for subjects with moderate and mild hepatic impairment (Cohorts 1 and 2) will initiate first and these subjects will be enrolled in parallel.
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE STUDY TO COMPARE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-04965842 IN ADULT SUBJECTS WITH MILD AND MODERATE HEPATIC IMPAIRMENT RELATIVE TO SUBJECTS WITH NORMAL HEPATIC FUNCTION
• Actual Study Start Date: October 1, 2018
• Actual Primary Completion Date: April 30, 2019
• Actual Study Completion Date: April 30, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: PF-04965842; PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.	Drug: PF-04965842; PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.

Outcome Measures

Primary Outcome Measures :

1. Maximum Observed Plasma Concentration (Cmax) for PF-04965842 [ Time Frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72 hours post-dose in each cohort ]
   Cmax is maximum plasma concentration. It was observed directly from data.
2. Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) for PF-04965842 [ Time Frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72 hours post-dose in each cohort ]
   AUCinf is area under the concentration-time curve (AUC) from time 0 (pre-dose) extrapolated to infinite time.

Secondary Outcome Measures :

1. Number of Participants With Treatment-Emergent Adverse Events (AEs) for PF-04965842 [ Time Frame: From screening (within 28 days prior to Day 1) till up to 36 days post-dose, the total maximum duration was approximately 63 days for individual participants. ]
   Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent adverse events (TEAEs) were those with initial onset or increasing in severity between the first dose of investigational product and up to 36 days post-dose.
2. Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) [ Time Frame: Screening (within 28 days prior to Day 1), Day -1, 2, 24, 72 hours post-dose. ]
   Laboratory tests included tests that were performed under the categories of hematology, chemistry, urinalysis, other, and additional tests needed for Hy's law.
3. Number of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance for PF-04965842 [ Time Frame: Screening (within 28 days prior to Day 1), Day -1, 2, 72 hours post-dose. ]
   12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. Clinical significance of ECG recordings was determined at the investigator's discretion.
4. Number of Participants With Vital Sign Findings of Potential Clinical Importance for PF-04965842 [ Time Frame: Screening (within 28 days prior to Day 1), 0 (pre-dose), and 72 hours post-dose. ]
   Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant following at least 5 minutes of supine rest. Clinical significance of vital signs was determined at the investigator's discretion.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Body mass index (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 pounds).
• Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Additional Inclusion Criteria for subjects with hepatic impairment:

• Satisfy the criteria for Class A or Class B of the Child Pugh classification (mild: Child Pugh Scores 5 to 6 points, and moderate: Child Pugh Scores 7 to 9 points), within 14 days of investigational product administration.
• A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver biopsy, hepatic ultrasound, computerized tomography scan, or magnetic resonance imaging (MRI).

Exclusion Criteria:

• Subjects with clinically significant infections within the past 3 months (for example, those requiring hospitalization, or as judged by the Investigator), evidence of any infection (including influenza) within the past 7 days, history of disseminated herpes simplex infection or recurrent (>1 episode) or disseminated herpes zoster.
• Subjects with a malignancy or with a history of malignancy, with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.

Additional exclusion criteria for subjects with hepatic impairment:

• Hepatic carcinoma or hepatorenal syndrome or limited predicted life expectancy (defined as less than 1 year).
• Subjects who have previously had a transplanted kidney, liver, or heart.
• At Screening, persistent severe, uncontrolled hypertension.

Contacts and Locations

Locations

United States, Florida

Orlando Clinical Research Center

Orlando, Florida, United States, 32809

United States, Minnesota

Prism Clinical Research, LLC

Saint Paul, Minnesota, United States, 55114

Sponsors and Collaborators

Pfizer

Investigators

• Study Director: Pfizer CT.gov Call Center; Pfizer

  Study Documents (Full-Text)

Documents provided by Pfizer:

Study Protocol  [PDF] July 23, 2018

Statistical Analysis Plan  [PDF] August 22, 2018

More Information

Additional Information:

To obtain contact information for a study center near you, click here. 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis. Clin Pharmacokinet. 2022 Jan 21. doi: 10.1007/s40262-021-01104-z. [Epub ahead of print] Erratum in: Clin Pharmacokinet. 2022 Feb 18;:.

Wang EQ, Le V, O'Gorman M, Tripathy S, Dowty ME, Wang L, Malhotra BK. Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. J Clin Pharmacol. 2021 Oct;61(10):1311-1323. doi: 10.1002/jcph.1858. Epub 2021 Apr 17.

• Responsible Party: Pfizer
• ClinicalTrials.gov Identifier: NCT03626415
• Other Study ID Numbers: B7451020
• First Posted: August 13, 2018
• Results First Posted: May 18, 2020
• Last Update Posted: May 18, 2020
• Last Verified: April 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:

Liver Diseases; Digestive System Diseases; Abrocitinib; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action